All In Biotech

Drug Trial Radar · NCT02754765

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial

Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 754 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

754

Actual

Start

Dec 2016

Primary completion

Jun 2023

Study completion Jun 2023

Sponsor

Lead sponsor
Médecins Sans Frontières, FranceAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Partners in Health; Harvard Medical School (HMS and HSDM); Epicentre; Institute of Tropical Medicine, Belgium; Socios En Salud, Peru; Interactive Research and Development
First posted
Apr 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).

Conditions

  • Tuberculosis, Multidrug-Resistant
  • Infection, Bacterial
  • Pulmonary Tuberculoses

Interventions

  • BedaquilineDrug

  • DelamanidDrug

  • ClofazimineDrug

  • LevofloxacinDrug

  • MoxifloxacinDrug

  • LinezolidDrug

  • PyrazinamideDrug

  • Control arm MDR-TB regimen, consistent with WHO guidelinesDrug

    Control arm MDR-TB regimen, consistent WHO guidelines

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Week 73 EfficacyTime frame: Week 73 after randomization

Locations

12 sites in 7 countries. Site status is shown where the registry gives one.

  • National Center for Tuberculosis and Lung Diseases

    Tbilisi, Georgia

  • Aundh Chest Hospital

    Pune, India

  • City Centre of Phthisiopulmonology

    Almaty, Kazakhstan

  • Center of Phthisiopulmonology of Almaty Health Department

    Almaty, Kazakhstan

  • National Center for Tuberculosis Problems

    Almaty, Kazakhstan

  • Partners In Health Lesostho

    Maseru, Lesotho

  • The Indus Hospital

    Karachi, Pakistan

  • Institute of Chest Disease,

    Kotri, Pakistan

  • Centro de Investigación del Hospital Nacional Hipólito Unanue

    Lima, Peru

  • Centro de Investigación de Enfermedades Neumológicas del Hospital Nacional Sergio Bernales

    Lima, Peru

  • Hospital Nacional Dos de Mayo Parque Historia de la Medicina

    Lima, Peru

  • Medecins Sans Frontieres Belgium

    Khayelitsha, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.